Aetna CEO and Chairman Mark Bertolini talked to CNBC about earnings, drug prices and needed changes to Obamacare. » Read More
Drugmaker AbbVie said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.
Outgoing Valeant CEO Michael Pearson plans to tell a U.S. Senate panel that it was a "mistake" to jack up the price of two life-saving heart drugs.
Boston Scientific rose after the firm reported better-than-expected quarterly results.
Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline's sales figures 8 percent.
The ex-Citigroup chair and his family foundation have donated $185M to the UCSF to establish the UCSF Weill Institute for Neurosciences.
The 300 million pain prescriptions written last year equal a $24B market, but it's not a market evenly divided around the globe.
Valeant, whose stock has plunged amid probes into its drug pricing, is too mired in debt to recover, an analyst said.
BP's message to other oil companies in the first quarter was loud and clear, CNBC's Jim Cramer says.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
Advisers to the FDA voted on Monday not to recommend approval of possibly the first drug for Duchenne muscular dystrophy, the New York Times reports.
Eli Lilly reports lower-than-expected earnings due largely to heavy spending on research.
Scientists are one step closer in harnessing the power of genome sequencing to help improve the diagnosis and treatment of autism.
For doctors and nurses in a growing number of hospitals, worrying about security when they input data into computers requires a balancing act.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Major food companies use downsizing as a tactic to hedge against increasing pressure to cut calories in processed foods, USA Today reports.
Shares of Sarepta Therapeutics plunge after the FDA maintains its "negative" outlook on the company's drug for a rare muscle-wasting disorder.
Novartis is discussing options with banks for selling its $13.8 billion stake in rival Roche, though a sale is not imminent.
Dick Kovacevich defended the embattled lab testing start-up's boss, Elizabeth Holmes, saying her treatment recently has been unfair.
The broader U.S. stock market has only seen slight gains this year, but shares of GW Pharmaceuticals are flying high in 2016.
When it comes to the explosion of opioid abuse in the U.S., large employers are footing a big chunk of the bill.
Get the best of CNBC in your inbox